Atogepant
Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist used for the preventive treatment of episodic migraine in adults. By blocking CGRP receptors, it reduces the frequency and severity of migraine attacks. It belongs to the gepant class of medications and is taken orally.
Atogepant is an oral CGRP receptor antagonist used to prevent episodic migraine attacks in adults.
Key facts at a glance
- ATC
- N02CD07
- RxNorm
- 2571813
- Generic
- Atogepant
- Class
- atc-n02
- Brands
- Qulipta
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- tablet
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 60mg once daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- not FDA approved for pediatric use
- Maximum
- consult physician
- Frequency
- N/A
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 60mg once daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
9 groupspregnancy
generalavoid if possible
Use only if benefits outweigh potential risks to the fetus
Regular fetal monitoring recommended
Use with caution and monitor for adverse effects.
pregnancy
first trimesteravoid if possible
Avoid use during first trimester unless benefits outweigh risks
Regular fetal monitoring
Use with caution and monitor for adverse effects.
lactation
breastfeedinguse with caution
Breastfeeding not recommended during treatment; discontinue breastfeeding or stop drug
Monitor infant for adverse effects
geriatric
elderlyno adjustment required
Use standard dosing; monitor for adverse effects
Standard clinical monitoring
Use with caution and monitor for adverse effects.
pediatric_age
under 18not recommended
Not approved for use in patients under 18 years of age
Not applicable
Use of this medication in this population requires careful consideration of risks and benefits.
renal_impairment
mildno adjustment required
No dose adjustment needed for mild renal impairment
Standard monitoring
renal_impairment
moderate to severeuse with caution
Use with caution; no specific dose adjustment required based on pharmacokinetics
Monitor renal function periodically
Use with caution and monitor for adverse effects.
hepatic_impairment
mild to moderateno adjustment required
No dose adjustment needed for mild to moderate hepatic impairment
Standard monitoring
hepatic_impairment
severeuse with caution
Use with caution; limited data available for severe hepatic impairment
Monitor liver function tests
Use with caution and monitor for adverse effects.
Statistics and clinical data
FDA approval year
First FDA approval date for migraine prevention
Drug class
Pharmacological classification
Indication
Therapeutic indication
Route of administration
Method of drug delivery
Preventive treatment of episodic migraine in adults who experience 4-14 migraine days per month. It is not indicated for acute migraine attacks or for preventive treatment of chronic migraine.
Atogepant selectively blocks CGRP receptors, preventing CGRP from binding and triggering the inflammatory and pain signaling cascades that contribute to migraine attacks.
Take as directed, typically once daily with or without food. Not for acute migraine relief. Inform your doctor of liver or kidney problems. Common side effects may include nausea, fatigue, and constipation. Avoid use during pregnancy unless clearly necessary.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy